StrykerSYK
Recorded

Stryker 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 1 minParticipants20

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the third quarter 2026 Stryker earnings call. My name is Layla, and I will be your conference operator for today's call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question and answer session. This conference call is being recorded for replay purposes. Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release that is an exhibit to Stryker's current report on Form 8-K filed today with the SEC. I will now turn the call over to Mr. Kevin Lobo, Chair and Chief Executive Officer.

Kevin LoboChair and CEO

You may proceed, sir. Welcome to Stryker's third quarter earnings call.

Kevin LoboChair and CEO

Joining me today are Preston Wells, CFO, and Nick Mead, Vice President of Investor Relations. Before I begin, I would like to congratulate Spencer Stiles on his appointment as Stryker's next CEO. Spencer has spent nearly three decades at Stryker helping shape our strategy, strengthen our culture, and drive our growth. You will have additional opportunities to hear more from him at various investor events over the next few months, and I am confident you will come away with an even greater appreciation of his capabilities to lead Stryker into the future. For today's call, I will provide an overview of our performance. Nick will then provide a brief M&A update, followed by Preston with additional details on financial results and guidance. We will then open the call to Q&A. Turning to our third quarter performance.

Kevin LoboChair and CEO

Organic sales growth for the quarter was 7.7%, with 9.1% growth in MedSurg and Neurotechnology and 5.9% growth in Orthopaedics. Our Endoscopy and Ortho Tech divisions delivered double-digit performances, and Medical also delivered near double-digit growth. While we delivered solid growth in several businesses, our overall results fell short of our expectations. As Preston mentioned during an investor conference in September, we are facing challenges with our hip and knee and peripheral vascular businesses. Beginning with hips and knees, it is now clear that there is a market slowdown. In the U.S., we are seeing slower procedural growth amid affordability concerns from higher insurance premiums and deductibles. We are also observing increased pre-authorization denials, creating additional friction and delaying patient access to treatment. Europe and the Middle East have also remained soft amid regional disruption, strike-related delays, and government funding decisions.

Kevin LoboChair and CEO

In addition to the softer market, we have not been winning at our historical rate. 2026 has been an unusual year, marked by the cyber incident in the first quarter and an SAP implementation within our Orthopaedics businesses in July. This is the last of our businesses to go on to SAP, and while the system is functioning well, it has created a distraction for our teams and delayed our visibility of market conditions. Although Mako sales have been strong again this year, we are behind our expectations on new product sales from Mako RPS and Triathlon Gold. The feedback on these innovations is very positive, but the cyber incident and SAP implementation have impacted our commercial execution. We are taking actions to improve competitive conversions and new product adoption.

Kevin LoboChair and CEO

Finally, as a leader in power tools, we are excited about bringing a powered hip impactor solution to the market next year, addressing an important product gap in our hip portfolio. We remain confident in the long-term attractiveness of the large joint reconstruction market, supported by favorable demographics and expanded access through new sites of care such as ASCs. Next, I'd like to give an update on our Vascular business, which reflects a sequential improvement from last quarter. The third quarter included one-time revenue from our peripheral vascular joint venture in China as a result of achieving a regulatory approval milestone in September. This benefit helped offset the impact of lost revenue from the ongoing supply disruption that we discussed during our last earnings call.

Kevin LoboChair and CEO

Our team has made meaningful progress restoring supply throughout the quarter, and we now expect inventory levels and product availability to continue normalizing through the end of the year. While this has been a challenging period, we remain convicted in the outlook for peripheral vascular as a growth business accretive to Stryker. Looking ahead to 2027, we expect to begin commercializing AVS's IVL platform and also look forward to important data from our PEERLESS II study of FlowTriever. We are excited about our recently announced strategic investment in CMR Surgical, which Nick will cover in his section. Our updated organic sales guidance anticipates a similar overall organic growth rate for the company in Q4 as we achieved in Q3. This assumes a continuation of the procedure environment we observed this quarter, as well as continued strong capital demand, where we continue to maintain an elevated order book.

Kevin LoboChair and CEO

Meanwhile, our successful efforts on margin expansion are limiting the impact of our sales shortfall on adjusted EPS, and we continue to generate strong cash flows. As this is the last of 57 earnings calls as CEO, I would have preferred to deliver better news, but we've demonstrated before that our business is resilient, our foundation and culture are strong, and we remain confident in our ability to deliver on our long-range financial commitments. I will now turn the call over to Nick.

Nick MeadVP of Investor Relations

Thank you, Kevin. My comments today will focus on M&A and will highlight two recent transactions.

Nick MeadVP of Investor Relations

As announced earlier this week, we have completed our acquisition of ZuriMED, which expands the support we can provide to specialists across sports medicine and arthroplasty. ZuriMED's differentiated FiberLocker technology is designed to increase biomechanical strength in rotator cuff repair and provides a broader platform for orthopedic soft tissue augmentation. Next, we recently announced an investment in CMR Surgical, an agreement to act as the exclusive U.S. sales agent for the Versius platform. Soft tissue robotics is an attractive adjacency that is a natural extension of Stryker's strengths in endoscopy, visualization, and enabling technologies. Versius has been used in more than 50,000 procedures globally, and its scalable design can support broader adoption of robotic-assisted surgery.

Nick MeadVP of Investor Relations

With its new Versius Plus system, approved indications, technology, and growing global clinical experience, we believe now is the right time to partner with CMR and begin scaling the U.S. market through a thoughtful and disciplined approach. Together, these transactions reflect our continued focus on investing in opportunities that support durable long-term growth and value creation. I will now turn the call over to Preston to further discuss our third quarter financial performance.

Preston WellsCFO

Thanks, Nick. Detailed financial information is included in today's press release. I will focus on our third quarter financial performance, the key drivers of our results, and our updated outlook for the remainder of the year. Organic sales grew 7.7% in the quarter against strong prior year comparable. Pricing contributed 0.1% to growth, while foreign currency had no impact on sales. The quarter had the same number of selling days as the prior year quarter. Adjusted earnings per share were $3.52, up 10.3% from the same quarter last year, driven by gross margin expansion supported by operational efficiencies, along with disciplined expense management. Turning to segment performance, MedSurg and Neurotechnology organic sales grew 9.1%, with growth of 9.6% in the U.S. and 7.2% internationally. Instruments U.S. organic sales grew 4.8% against a strong 15.3% prior year comparable, with double-digit growth in our interventional spine and surgical technologies businesses.

Preston WellsCFO

This performance was offset by softer performance in our neurosurgical business due to the deferral of capital purchases ahead of the upcoming launch of our Sonopet 3 ultrasonic aspiration platform, which received FDA 510(k) clearance earlier this month. Endoscopy U.S. organic sales grew 13%, supported by continued robust demand for operating room infrastructure and renovations, and strong performance in sports medicine, where double-digit growth continues to be driven by its expanded range of shoulder implant products. Medical U.S. organic sales increased 10%, including double-digit performances from Sage and Smart Care businesses, while capital demand remains elevated across our portfolio. Vascular U.S. organic sales grew 13%, primarily reflecting the drivers that Kevin discussed earlier. Internationally, MedSurg and Neurotechnology organic sales growth of 7.2% included broad strength across endoscopy, medical, and instruments. Geographically, growth was led by robust performances in Australia, Germany, Canada, and India.

Preston WellsCFO

Orthopaedics organic sales grew 5.9%, with growth of 6.4% in the U.S. and 4.4% internationally. U.S. knees organic sales grew 1.3%, while U.S. hips organic sales declined 0.6% against strong prior year comparables. As Kevin noted, we remain focused on strengthening our commercial execution behind our enabling technology platforms and new products to restore momentum and drive share gains. U.S. Trauma and Extremities organic sales grew 4.5% against a strong 13.2% prior year comparable. Current year growth reflected continued strong performance in upper extremities, supported by continued momentum across our differentiated portfolio, including early success of Mako Shoulder on Mako 4. We are expecting strong growth for Trauma and Extremities in the fourth quarter. U.S. Ortho Tech organic sales increased 18%, supported by continued strength in Mako sales and robust demand for orthopaedic power tools.

Preston WellsCFO

Internationally, Orthopaedics organic sales grew 4.4%, supported by knees, Ortho Tech, and Trauma and Extremities, and was led regionally by Canada, Japan, Australia, Germany, and India. Turning to margins and other income statement items. Adjusted gross margin was 65.4%, up 40 basis points from the third quarter of 2025. The improvement reflected a net tariff benefit and benefits from operational efficiencies. Adjusted operating margin was 26.2% of sales, up 60 basis points from the third quarter of 2025, reflecting the gross margin improvement and continued expense discipline. Adjusted other income and expense was $91 million, down $25 million from the same quarter last year, reflecting lower debt levels. We now expect adjusted other income and expense to be approximately $400 million for the full year.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day